Lydiard R B, Lesser I M, Ballenger J C, Rubin R T, Laraia M, DuPont R
Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston 29425.
J Clin Psychopharmacol. 1992 Apr;12(2):96-103.
A recently reported multinational, 8-week double-blind, placebo-controlled study assessing the efficacy of alprazolam versus placebo in the treatment of panic disorder indicated significant differences favoring alprazolam. We now report the results of a three-site, 6-week, double-blind, fixed-dose study comparing alprazolam 2 mg, alprazolam 6 mg, and placebo in 94 patients with panic disorder with or without agoraphobia. Both alprazolam treatment groups (6 mg and 2 mg) improved significantly more than did the placebo treatment group on most outcome measures. Only a few statistically significant differences between the 6 mg and 2 mg alprazolam groups were discerned, although the pattern of treatment response across measures suggested a dose effect. Dropouts in the placebo group were primarily due to lack of efficacy and in the alprazolam 6 mg group were due to side effects, which may have contributed to the limited differences between groups at study end. The findings suggest that many patients may require less than 6 mg of alprazolam per day for effective treatment of panic disorder.
最近一项关于阿普唑仑与安慰剂治疗惊恐障碍疗效对比的多中心、为期8周的双盲、安慰剂对照研究表明，两者存在显著差异，阿普唑仑疗效更佳。我们现在报告一项三中心、为期6周的双盲、固定剂量研究结果，该研究对94例伴有或不伴有广场恐惧症的惊恐障碍患者使用2毫克阿普唑仑、6毫克阿普唑仑和安慰剂进行了比较。在大多数疗效指标上，两个阿普唑仑治疗组（6毫克组和2毫克组）的改善程度均显著高于安慰剂治疗组。虽然在各项指标上的治疗反应模式显示出剂量效应，但在6毫克阿普唑仑组和2毫克阿普唑仑组之间仅发现了少数具有统计学意义的差异。安慰剂组的退出主要是因为疗效不佳，而6毫克阿普唑仑组的退出则是由于副作用，这可能是导致研究结束时两组差异有限的原因。研究结果表明，许多患者每天可能只需服用低于6毫克的阿普唑仑就能有效治疗惊恐障碍。
